Company news

Liminal BioSciences Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Liminal BioSciences to Voluntarily Delist from the Toronto Stock Exchange

July 22, 2020

Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases

July 17, 2020

Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy

July 2, 2020

Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors

June 30, 2020

Liminal BioSciences Provides Guidance Update on Certain Expected Key Milestones For 2020

June 30, 2020

Liminal BioSciences to Present at Raymond James Human Health Innovation Conference

June 11, 2020

Liminal Announces Voting Results of Its 2020 Annual And Special General Meeting Of Shareholders (AGM)

June 9, 2020

Liminal BioSciences to present at Jefferies Virtual Healthcare Conference

May 28, 2020

Liminal Biosciences Reports Q1 2020 Results

May 13, 2020

Liminal BioSciences comments on Coronavirus (COVID-19)

March 22, 2020

Liminal Biosciences Reports Fourth Quarter and 2019 Year End Results

March 20, 2020

Liminal BioSciences to report its fourth quarter and year-end 2019 financial results and hold conference call/webcast

March 20, 2020

Liminal BioSciences Announces Scientific Presentations at Upcoming Keystone Symposia

February 12, 2020

Liminal BioSciences announces upcoming investor presentation at BIO CEO & Investor Conference

February 6, 2020

Liminal BioSciences Outlines Corporate Priorities for 2020

January 13, 2020

Liminal BioSciences Comments on Unusual Market Activity

December 23, 2019

AMF Concludes its Review of the Refinancing Transactions Completed by Liminal BioSciences in April 2019

November 28, 2019

Liminal BioSciences to Present at Piper Jaffray Healthcare Conference

November 27, 2019

Liminal BioSciences announces closing of divestiture of bioseparations division to KKR

November 25, 2019

Liminal Presents New Preclinical Data on PBI-4050 and its Effect on Angio-Proliferative Pulmonary Arterial Hypertension

November 18, 2019

Liminal BioSciences to Present at the Jefferies 2019 London Healthcare Conference

November 18, 2019

Liminal Biosciences announces effectiveness of Registration Statement on Form F-10 and filing of Prospectus Supplement

November 18, 2019

Liminal BioSciences to Present at Stifel Healthcare Conference

November 15, 2019

Liminal BioSciences to Commence Trading Common Shares on NASDAQ

November 15, 2019

/C O R R E C T I O N from Source -- Liminal BioSciences Inc./

November 14, 2019

Liminal Biosciences Announces Key Appointment to its Leadership Team

November 13, 2019

Liminal BioSciences Presents New Preclinical Data on PBI-4050 and NASH Candidate PBI-4547

November 12, 2019

Liminal BioSciences to Report Q3 2019 Results and Hold Conference Call

November 11, 2019

Liminal BioSciences Reports its 2019 Third Quarter Financial Results and Business Highlights

November 11, 2019

Liminal Biosciences Presents New Preclinical Data at ASN Kidney Week 2019

November 11, 2019

Liminal BioSciences to Divest Bioseparations Division to KKR

November 4, 2019

Liminal BioSciences announces upcoming presentations new data on pulmonary arterial hypertension at the 2019 AHA meeting

October 29, 2019

Liminal BioSciences announces upcoming presentations at The Liver Meeting 2019

October 25, 2019

Liminal BioSciences Announces Upcoming Presentations at ASN Kidney Week 2019

October 24, 2019

Liminal BioSciences to Present At H.C. Wainwright & Co. 3rd Annual NASH Investor Conference

October 18, 2019

Prometic Shareholders Approve Name Change to Liminal BioSciences Inc.

October 3, 2019

Prometic Life Sciences Announces Intention to Change Name to Liminal BioSciences Inc.

September 3, 2019

Calls

Decks

The 5 newest of 6 decks. Every deck is listed under its year.